Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review

Overview

Journal Behav Neurol

Publisher Wiley

Specialty Psychiatry

Date 2023 Oct 23

PMID 37868743

Authors

Kuldeep Singh

Bharat Bhushan

Dilip Kumar Chanchal

Satish Kumar Sharma

Ketki Rani

Manoj Kumar Yadav

Prateek Porwal

Shivendra Kumar

Ashwani Sharma

Tarun Virmani

Girish Kumar

Abdullah Al Noman

Affiliations

Soon will be listed here.

Abstract

Cannabidiol (CBD), derived from Cannabis sativa, has gained remarkable attention for its potential therapeutic applications. This thorough analysis explores the increasing significance of CBD in treating neurological conditions including epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's disease, which present major healthcare concerns on a worldwide scale. Despite the lack of available therapies, CBD has been shown to possess a variety of pharmacological effects in preclinical and clinical studies, making it an intriguing competitor. This review brings together the most recent findings on the endocannabinoid and neurotransmitter systems, as well as anti-inflammatory pathways, that underlie CBD's modes of action. Synthesized efficacy and safety assessments for a range of neurological illnesses are included, covering human trials, in vitro studies, and animal models. The investigation includes how CBD could protect neurons, control neuroinflammation, fend off oxidative stress, and manage neuronal excitability. This study emphasizes existing clinical studies and future possibilities in CBD research, addressing research issues such as regulatory complications and contradicting results, and advocates for further investigation of therapeutic efficacy and ideal dose methodologies. By emphasizing CBD's potential to improve patient well-being, this investigation presents a revised viewpoint on its suitability as a therapeutic intervention for neurological illnesses.

Citing Articles

A systematic study of molecular targets of cannabidiol in Alzheimer's disease.

Patil N, Patil K, Jain M, Mohammed A, Yadav A, Dhanda P J Alzheimers Dis Rep. 2025; 8(1):1339-1360.

PMID: 40034365 PMC: 11863746. DOI: 10.1177/25424823241284464.

Therapeutic Application of Modulators of Endogenous Cannabinoid System in Parkinson's Disease.

Khaspekov L, Illarioshkin S Int J Mol Sci. 2024; 25(15).

PMID: 39126088 PMC: 11312457. DOI: 10.3390/ijms25158520.

Protective Effects of Cannabidiol (CBD) against Qxidative Stress, but Not Excitotoxic-Related Neuronal Cell Damage-An In Vitro Study.

Jantas D, Leskiewicz M, Regulska M, Procner M, Warszynski P, Lason W Biomolecules. 2024; 14(5).

PMID: 38785971 PMC: 11117811. DOI: 10.3390/biom14050564.

Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer's Disease.

Hickey J, Collins A, Nelson M, Chen H, Kalisch B Curr Issues Mol Biol. 2024; 46(5):4379-4402.

PMID: 38785534 PMC: 11120237. DOI: 10.3390/cimb46050266.

CBD and THC in Special Populations: Pharmacokinetics and Drug-Drug Interactions.

Qian L, Beers J, Jackson K, Zhou Z Pharmaceutics. 2024; 16(4).

PMID: 38675145 PMC: 11054161. DOI: 10.3390/pharmaceutics16040484.

References

Galiegue S, MARY S, Marchand J, Dussossoy D, Carriere D, Carayon P . Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995; 232(1):54-61. DOI: 10.1111/j.1432-1033.1995.tb20780.x. View

Batalla A, Janssen H, Gangadin S, Bossong M . The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review. J Clin Med. 2019; 8(7). PMC: 6678854. DOI: 10.3390/jcm8071058. View

Kaplan E, Offermann E, Sievers J, Comi A . Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome. Pediatr Neurol. 2017; 71:18-23.e2. DOI: 10.1016/j.pediatrneurol.2017.02.009. View

Kwiatkoski M, Guimaraes F, Del-Bel E . Cannabidiol-treated rats exhibited higher motor score after cryogenic spinal cord injury. Neurotox Res. 2011; 21(3):271-80. DOI: 10.1007/s12640-011-9273-8. View

Efron D, Taylor K . Medicinal Cannabis for Paediatric Developmental, Behavioural and Mental Health Disorders. Int J Environ Res Public Health. 2023; 20(8). PMC: 10138057. DOI: 10.3390/ijerph20085430. View

Henson J, Vitetta L, Hall S . Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions. Inflammopharmacology. 2022; 30(4):1167-1178. PMC: 9294022. DOI: 10.1007/s10787-022-01020-z. View

Micale V, Di Marzo V, Sulcova A, Wotjak C, Drago F . Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol Ther. 2012; 138(1):18-37. DOI: 10.1016/j.pharmthera.2012.12.002. View

Chayasirisobhon S . The Role of Cannabidiol in Neurological Disorders. Perm J. 2021; 25. PMC: 8817911. DOI: 10.7812/TPP/20.156. View

Segerstrom S, Miller G . Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychol Bull. 2004; 130(4):601-30. PMC: 1361287. DOI: 10.1037/0033-2909.130.4.601. View

10.

Lowe H, Toyang N, Steele B, Bryant J, Ngwa W . The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases. Int J Mol Sci. 2021; 22(17). PMC: 8430969. DOI: 10.3390/ijms22179472. View

11.

Szaflarski J, Bebin E, Cutter G, DeWolfe J, Dure L, Gaston T . Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy Behav. 2018; 87:131-136. DOI: 10.1016/j.yebeh.2018.07.020. View

12.

Rani V, Verma R, Kumar K, Chawla R . Role of pro-inflammatory cytokines in Alzheimer's disease and neuroprotective effects of pegylated self-assembled nanoscaffolds. Curr Res Pharmacol Drug Discov. 2023; 4:100149. PMC: 9804106. DOI: 10.1016/j.crphar.2022.100149. View

13.

Morais H, de Souza C, Silva L, Ferreira D, Baggio C, Vanvossen A . Anandamide reverses depressive-like behavior, neurochemical abnormalities and oxidative-stress parameters in streptozotocin-diabetic rats: Role of CB1 receptors. Eur Neuropsychopharmacol. 2016; 26(10):1590-600. DOI: 10.1016/j.euroneuro.2016.08.007. View

14.

Llorente-Berzal A, Terzian A, Di Marzo V, Micale V, Viveros M, Wotjak C . 2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons. Psychopharmacology (Berl). 2015; 232(15):2811-25. DOI: 10.1007/s00213-015-3917-y. View

15.

Stella B, Baratta F, Pepa C, Arpicco S, Gastaldi D, Dosio F . Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain. Drugs. 2021; 81(13):1513-1557. PMC: 8417625. DOI: 10.1007/s40265-021-01579-x. View

16.

Wang Y, Hong Y, Yan J, Brown B, Lin X, Zhang X . Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice. Int J Mol Sci. 2022; 23(5). PMC: 8910894. DOI: 10.3390/ijms23052757. View

17.

Xu C, Chang T, Du Y, Yu C, Tan X, Li X . Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model. Environ Toxicol Pharmacol. 2019; 70:103202. DOI: 10.1016/j.etap.2019.103202. View

18.

Pisanti S, Malfitano A, Ciaglia E, Lamberti A, Ranieri R, Cuomo G . Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017; 175:133-150. DOI: 10.1016/j.pharmthera.2017.02.041. View

19.

Ozarowski M, Karpinski T, Zielinska A, Souto E, Wielgus K . Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action. Int J Mol Sci. 2021; 22(9). PMC: 8122338. DOI: 10.3390/ijms22094294. View

20.

Sholler D, Schoene L, Spindle T . Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies. Curr Addict Rep. 2021; 7(3):405-412. PMC: 7880228. DOI: 10.1007/s40429-020-00326-8. View